Dimitrios H Roukos
Ioannina University, Greece
Roukos DH, Ioannina University, Greece. Dimitrios Roukos, MD (Athens University, Greece), PhD (J.W.Goethe University, Frankfurt a.M., Germany), has moved his scientific interest after 25 years of reductionist medicine to network biology-based systems medicine. Assessing the clinical limitations of current traditional medicine to cure in the future incurable diseases such as cancer, has focused over the last 5 years on human cancer genome both structural variation and functional heterogeneity. His emerging goal is to understand how inherited and somatic mutations, epigenome, transcriptome and interactome abnormalities change chromatin dynamic states and gene expression. Emerging evidence suggests that this gene dysfunction and deregulation of cell signalling pathways drive tumorigenesis and metastasis. His ultimate goal is to approach next-generation anticancer drugs and biomarkers to future achievement of personalized medicine and network biology-based managment of cancer.Publication metrics: > 200 papers with ~ 5,000 citations (h=55) in PubMed, ISI, Scopus and current editor of two eBooks on personalized management of cancer and cancer genome heterogeneity-based treatment of cancer. Currently is key evaluator in European Commission (FP7 Systems Medicine area) and French National Research Agency (22 billion euros) participating in experts panel meeting in Brussels and Paris (end 2011) for the selection of best projects. He is leader of Translational Research in European Union Network of Excellence (EUNE) for gastric cancer and Personalized Cancer Genomic Medicine, Biobank in Ioannina University (Greece). He has been invited speaker and consensus member in multiple International Cancer Meetings. He serves as Editor-in-Chief, Associate Editor and Editorial board member in 20 influential journals.
Assessing limitations of conventional reductionist medicine, he have shifted to multi-scale genes, proteins, molecules, DNA, and RNA interactions in physical and functional networks. Revolutionary NGS technologies provide mow sequencing of DNA (whole genome, exome), transcriptome (RNA-seq, Chip-seq), epigenome (BS-seq) and also along with novel techniques (living cells imaging and computational models) also deeper insights into the grand challenge of interactome (multidimensional spatiotemporal protein-protein interactions). Integrating all these experimental data (omics, living-cells imaging, 3D-genome resolution and intra- and inter-cellular differentiation mapping) and large-scale clinical data into computational models, deep understanding of a personal genome code-lifestyle interactions network is beginning to be shaped. The perspectives of future medicine based on clinical genome and systems science are now rationally excellent for revolutionizing healthcare.